Choosing the Right CDMO for CGT Programs

By Brian Mullan, PhD, Chief Technical Officer at Yposkesi.

Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products.

In the past 20 years, the contract development and manufacturing organization (CDMO) sector has grown strongly—initially in chemical manufacturing (outsourcing capacity for specialized manufacturing chemistries) and more recently for biopharmaceutical manufacturing, as parts of this sector have matured (e.g., monoclonal antibody therapeutics [mAbs]) (1).

Copyright: Published by Pharmaceutical Technology, Pharmaceutical Technology, October 2022, Volume 46, Issue 10; pages: 60–64.